U.S. License Holder:
Sandoz / Polpharma
Date of License:
aBLA accepted by FDA July-2022
Last Update:
August-15-2022
FDA-Approved Indications
PB006 (natalizumab) is not FDA-approved. An aBLA has been accepted by the FDA.